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1. Introduction  
Iodide (I-) is transported from bloodstream to lactating mammary gland tissue and it is 
secreted to mother’s milk (Honour et al., 1952; Grosvenor, 1960; Eskin et al., 1974; Bakheet et 
al., 1998). I- in milk is then used by the suckling newborn in thyroid hormone biosynthesis 
(Brown-Grant, 1957; 1961; Azizi and Smyth, 2009). As the supply of  I- to neonate comes 
exclusively from milk during first months of its life, I- uptake by lactocytes and its 
accumulation in mother’s milk is vital for proper development of the nervous system, 
skeletal muscles, and lungs at those early periods of life (Stanbury, 1992; Delange, 2000; 
Semba & Delange, 2001).  
The activity of the sodium/I- symporter (Na+/I- Symporter, or NIS) expressed in alveolar 
cells of lactating breast is essential for secretion of I- to milk (Cho et al., 2000; Tazebay et al., 
2000). In fact, by many clinicians and researchers, cellular I- transport activity was mostly 
associated with the thyroid gland as the I- uptake into thyroid follicular cells is the first step 
in enzymatic synthesis of iodide-containing thyroid hormones triiodothyronine (T3), and 
thyroxine (T4). Molecular investigations following the cloning of NIS gene by Dai et al. 
(1996) have proven that this symporter is not only a key enzyme in I- uptake in thyroid, but 
it is also functional in extrathyroidal tissues such as lactating mammary glands, stomach, 
intestine, salivary glands, kidney, and placenta (Ajjan et al., 1998; Tazebay et al., 2000; Bidart 
et al., 2000; Mitchell et al., 2001; Spitzweg et al., 2001; Nicola et al., 2009). Therefore, together 
with its key role in thyrocytes, NIS seems to be the long seeked (Wolff & Maurey, 1961) 
major I- transport protein in extrathyroidal tissues as well (De la Vieja et al., 2000). But, as 
one could expect, the expression and activity of NIS is differentially regulated in thyroid 
and in above mentioned non-thyroidal tissues (see below). 
In human, NIS is encoded by the gene annotated as Solute Carrier 5A5 (SLC5A5) in NCBI 
databases (www.http://www.ncbi.nlm.nih.gov). Among its other members, SLC5A 
transporter family includes Na+/glucose co-transporters 1 and 2, the Na+/myoinositol 
transporter, and the Na+/monocarboxylate transporter (Wright and Turk, 2004). The human 
NIS gene is located on chromosome 19, mapping to loci 19p13.2-p12 (Smanik et al., 1997). 
Previous extensive molecular studies carried out by Nancy Carrasco’s group at the Albert 
Einstein College of Medicine have revealed that the transporter is a glycoprotein belonging 
to the Na+/solute symporter family, and it is integrated to membrane by 13 hydrophobic 
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trans-membrane domains with N-terminus located extracellularly and C-terminus facing the 
cytosol (Dai et al., 1996; Levy et al., 1997; 1998). Rat NIS protein is composed of 618 amino 
acids, while its human homologue contains 643 residues with a relative molecular mass of 
about 75 kD to 110 kD depending on the glycosylation status of the protein in different 
tissues (Dai et al., 1996; Smanik et al., 1996; Tazebay et al., 2000).  
In order to establish biophysical properties of the transporter, the rat thyroid Na+/I- 
symporter (NIS) was expressed by Eskandari et al. (1997) in Xenopus laevis oocytes and the 
symporter was characterized using electrophysiological, tracer uptake, and electron 
microscopic methods. In this work, I- transport activity of NIS against its gradient was 
shown to couple the inward transport of Na+, occurring in favor of its Na+/K+-ATPase-
generated electrochemical gradient. Moreover, these authors have clearly shown that the 
transport activity was electrogenic, and the stoichiometry of cotransport by NIS was 2 Na+ 
ions to 1 I-. Interestingly, this work have also shown that other than I-, the symporter was 
capable of transporting a wide variety of anions such as, ClO3-, SCN-, SeCN-, NO3-, Br-, BF4-, 
IO4-, BrO3- (Eskandari et al., 1997). It also transports radioisotopes such as pertechnetate  
(99mTcO4-; Tazebay et al. 2000, Van Sande et al. 2003), perrhenate (188ReO4-; Dadachova et al. 
2002) and astatine (211At–; Lindencrona et al. 2001). Binding sites of these substrates on NIS 
protein, and their molecular interactions during passage through the symporter is not 
currently known. However, a recent publication on extensive mutational analysis carried 
out by Antonio De la Vieja and his co-workers indicated that particularly amino acids Thr-
351, Ser-353, Thr-354, Ser-356, Thr-357, Asn-360, and Asp-369, all of which either face the 
same side of the helix in trans-membrane segment IX or close to it at the membrane/cytosol 
interface (Asp-369) according to their current structural model, are involved in Na+ binding 
or translocation activity by NIS (De la Vieja et al., 2007). In fact, T354P mutation in NIS was 
previously identified as an autosomal recessive mutation resulting in iodide transport defect 
(ITD), a rare disorder causing congenital hypothyroidism in human (Fujiwara et al., 1998). 
In addition to its role in normal breast physiology during lactation, a very significant NIS 
upregulation as well as increased radioiodide transport activity was reported in large 
percentage of breast cancers and its metastasis (Tazebay et al., 2000; Wapnir et al., 2003; 2004; 
Upadhyay et al., 2003; Renier et al., 2009; 2010, and see below). These results indicate that 
NIS-mediated radionuclide imaging and therapy methods could potentially be used as 
alternative aproaches, or in combination with existing methodologies, towards a better 
management of the malignant breast disease, as it is routinely used against thyroid cancer 
and its metastasis for more than 60 years (Daniel & Haber, 2000; Welcsh & Mankoff, 2000; 
Spitzweg & Morris, 2002; Boelaert & Franklyn, 2003). Currently, breast cancer management 
involves adjuvant systemic therapies that are administered before or after mastectomy 
surgeries with the purpose of ablating micro-metastatic cells and improving disease free 
overall survival of the patient. In fact, it seems that neo-adjuvant and adjuvant therapies are 
rather successful, and they reduce recurrences by nearly 50% (Early Breast Cancer Trialist’s 
Collaborative Group, 1998; Citron et al., 2003). The administration of cytotoxic agents used 
in breast cancer chemotherapy is usually by venal intervention, and it can cause significant 
side effects, such as loss of healthy blood cells, increased possibilities to get microbial 
infections, hair loss, tiredness, feeling sick, sore mouth, sore eyes, and diarrhea. Patients and 
families are looking forward for development of alternative strategies that target breast 
cancer cells with high specificity, that are less toxic to healthy tissues and with less side-
effects. Because of previous, and decades long, clinical work in diagnosing and treating 
thyroid cancers by radioisotope substrates of NIS (131I-, 125I-, 123I-, or 99mTcO4-), use of NIS 
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transported radionuclides could offer novel prospective breast cancer treatment modalities 
with advantages such as, less toxicity to healthy tissues, easier administration procedures, 
and relatively less side-effects as compared to current chemotherapeutic drugs. However, as 
discussed in this chapter, a broader knowledge on molecular mechanisms that operate in 
modulation (upregulation and repression) of functional NIS expression in mammary gland 
is certainly required in order to achieve a better diagnostic and/or therapeutic effect on 
breast cancer by using radiolabelled substrates of the symporter.  
In this chapter, first, I am going to focus on the biological function of NIS in normal 
mammary gland epithelia. Then, recent studies on levels of NIS expression in different 
histopathological types of breast tumours will be analyzed. Subsequently, I will introduce 
recent findings on regulatory interplays, and small molecular agents that modulate NIS 
gene expression and activity both in normal mammary gland during gestation and lactation, 
and in malignant transformation in breast tissue. Recent in vivo animal studies, as well as 
human clinical trials addressing uses of NIS substrate radionuclides for imaging purposes 
will be introduced in later parts of this review. I will conclude by reviewing current 
litterature that analyze potential future strategies for the development of NIS radionuclide 
transport activity based therapeutic and diagnostic methods that could lead to novel clinical 
approaches in breast cancer management.  
2. Regulation of NIS expression during mammary gland development and in 
lactating breast 
I- accumulation in lactating mammary gland has been recognized for nearly 60 years 
(Honour et al., 1952; Brown-Grant, 1957; Grosvenor, 1960; Thorpe, 1976; Bakheet et al., 1998). 
In normal physiology, mammary gland accumulates I- only at later stages of gestation or 
pregnancy, and during lactation. An adequate supply of I- in mother’s milk is a must for 
sufficient thyroid hormone synthesis, which is essential for healthy development of the 
newborn. With molecular cloning of NIS gene in 1996, and subsequent generation of high 
affinity antibodies specific for human and rodent NIS proteins, researchers acquired 
essential tools to investigate whether NIS could have any role in the uptake of I- in lactating 
mammary glands. First the group of Spitzweg et al. (1998) by relatively simple RT-PCR 
methods, and later on groups of Cho et al. (2000), Tazebay et al. (2000), and Perron et al. 
(2001) with more sophisticated immunological and molecular biochemistry techniques have 
addressed expression of NIS in mammary glands of human or rodent experimental models. 
From results obtained in above mentioned studies, it is now clear that NIS is not expressed 
in non-lactating healthy mammary glands, and the expression of symporter rises above 
detectable limits in the mammary gland tissue only with the onset of gestation. 
Subsequently, NIS expression is up-regulated at transcription level concomitant to increased 
proliferation of lactocytes in the gland, and then, after delivery, its expression remain high 
exclusively in response to hormonal stimuli induced by suckling of nipples by newborn 
pups.  
2.1 Regulation of NIS expression during gestation in mice 
In developing mammary glands of healthy CD1(ICR)BR strain pregnant mice, NIS 
expression starts at mid-gestation, i.e. around days 10 or 11 in a full gestation period of 19 
days (Tazebay et al., 2000), and it becomes maximal near the end of gestation (days 18-19) 
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before delivery (Cho et al., 2000; Tazebay et al., 2000). Delivery is not essential for an 
increased uptake of I- to mammary glands during gestation, and accumulation of radio-
labelled substrates of NIS in the gland is observable in pregnant mice (Tazebay et al., 2000). 
By using immuno-histochemical techniques, NIS protein was detected on the basolateral 
membranes of alveolar epithelial cells of lactating mammary glands (Cho et al., 2000; 
Tazebay et al., 2000). These cells take up I- from the bloodstream and secrete it to milk for 
neonatal nutrition, leading to a concentration of I-up to 15 fold as compared to the plasma I- 
concentration (Nurnberger & Lippscomb, 1952; Thorpe, 1976). It is also important to note 
here that, about 20% of transported I- were found to be organified (i.e., inorganic I- 
conjugated to an organic molecule, or enzyme) by lactoperoxidases in the alveolar cells 
(Patrick, 2008). 
Thyroid gland, mammary glands, salivary glands, and stomach are tissues where most 
intense NIS expression is observed (Tazebay et al., 2000; Riedel et al., 2001). Even though, 
these tissues express NIS at relatively high levels, the timing of expression and stimuli for its 
up or down-regulation are not the same. In thyroid, thyroid stimulating hormone (TSH) that 
is synthesized and released by thyrotrope cells located in the anterior pituitary gland, is the 
main regulator of thyroid cell proliferation, differentiation, and endocrine functions, 
including molecular regulation of NIS expression both at transcriptional and at post-
translational levels (Levy et al., 1997; Riedel et al., 2001). The effects of TSH are primarily 
mediated through the activation of the cAMP cascade via the GTP-binding protein Gs. TSH 
stimulates iodide accumulation by positively regulating NIS expression at the protein and 
mRNA level via the cAMP pathway (Levy et al., 1997). Hypophysectomized rats with low 
circulating levels of TSH have a decreased protein expression of NIS, whereas a single 
injection of TSH leads to a robust increase in NIS expression. Rats maintained on an iodide-
deficient diet or treated with propylthiouracil, an agent blocking iodide organification, have 
high concentrations of TSH, which correlates with a very significant increase in NIS protein 
expression (Levy et al., 1997). The reader is advised to refer wonderful reviews by Dohan et 
al. (2003), or by Kogai et al. (2006) among many others for detailed information on TSH 
dependent regulation of thyroid specific genes including NIS. Even though NIS expression 
is continuous in the thyroid throughout life, in mammary glands it is strictly a 
gestation/lactation specific event, independent of blood TSH levels (Eskin et al., 1974; 
Tazebay et al., 2000; Kogai et al., 2006).  
In my opinion, a research student who for the first time observes mammary gland 
development in rodents by animal dissections will certainly be very much surprised in 
seeing tremendous size differences in mammary glands of virgin and lactating females. In 
virgin mice/rats, the organ is composed of a thin sheet of tissue close to skin, hard to find 
and dissect without previous experience. However, in lactating rodents, it is difficult not to 
notice them, because by size they are comparable to largest internal organs of the animal. 
This makes mammary glands invaluable experimental models for organ development and 
morphogenesis. It is branching morphogenesis of mammary gland epithelia that leads to 
formation of buds and milk ducts, and that characterizes mammary gland growth. In this 
developmental process, mammary specific molecular networks interpret signals from local 
cytokines/growth factors in both the epithelial and stromal microenvironments, which is 
orchestrated by secreted ovarian and pituitary hormones (McNally & Martin, 2011). Because 
I- transport and functional expression of NIS in the mammary gland is first observed at mid-
pregnancy, and during lactation, both us and others have inquired possible roles of ovarian 
and pituitary lactogenic hormones in regulation of NIS in mammary glands. In two 
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independent studies, steroid hormones estrogen (17--estradiol) and progesterone, and two 
pituitary lactogenic hormones, prolactin and oxytocin were administered to female virgin 
animals either one by one, or in different combinations, and their effects on NIS 
upregulation were monitored (Cho et al., 2000; Tazebay et al., 2000). In the study carried out 
by Tazebay et al. (2000), together with normal virgin female mice, the authors have also used 
ovariectomized females in order to prevent possible interferences between administered and 
endogenous steroid levels. In these work, it has been demonstrated that estrogen and the 
two pituitary hormones oxytocin and prolactin have up-regulatory roles in mammary gland 
NIS expression. Interestingly, estradiol was previously shown to down-regulate NIS 
expression in FRTL-5 rat thyroid cells under culture conditions (Furlanetto et al., 1999). On 
the contrary, in mammary gland cell lines in culture, major receptor that interacts with 
estradiols, estrogen receptor-alpha (ER-) was shown to be essential for basal expression of 
NIS in a ligand independent manner, and for its further induction in response to other non-
estrogenic extracellular factors (Alotaibi et al., 2006; and see below). Moreover, recently a 
significant positive correlation was reported between human NIS and ER- expressions in a 
cohort of malignant (n=75) or normal breast tissue (n=10) specimens (Ryan et al., 2011). 
In fact, the work carried out by Alotaibi et al. (2006) could connect these two seemingly 
conflicting results, and bring possible mechanistic explanations on how estrogens and ER 
dependent molecular mechanisms (in the presence or absence of their ligands) might have 
both positive and negative regulatory roles on NIS expression. In this work, first a clear 
correlation between the transcription factor ER- and activation of NIS expression was 
shown in human mammary epithelial cell models. Then, it has been demonstrated that ER- 
physically interacts with a novel responsive element (ERE) in NIS gene promoter, occupying 
this position under conditions where NIS activation is pronounced. It is important to precise 
here once again that regulation of NIS by ER system has some very uncommon 
characteristics. Unliganded ER- (Apo-ER) seems to be functional in basal expression of 
NIS, and it is shown to be essential to keep the system inducible by other ligands, namely by 
retinoids (see Part 5 below, for a detailed mechanistic analysis). Another interesting point is 
that mutations inserted to NIS ERE in a lusiferase reporter gene system have, in fact, 
increased transcription of the reporter in MCF-7 mammary tumor cells in culture conditions 
(Hani Alotaibi and U.H.T.; unpublished observations), instead of decreasing the expression 
of the reporter gene, as one would normally expect in classical ER regulated genes. These 
results might suggest the presence of a relatively complex and dynamic interplay between 
ER and other transcription factors (specific or general) operating on NIS gene promoter. 
Remarkably, the position of this novel functional NIS ERE sequence was precisely 
conserved in rodent and human genomes, and it was found to be localized only about 9 base 
pairs far from NIS gene TATA box element (Fig. 1; Alotaibi et al., 2006). The key point in this 
uncommon regulation of a gene (NIS) by ER may reside at this exceptionally close 
positioning between NIS ERE and TATA box elements. Speculatively, when concentrations 
of 17--estradiol raises above normal physiological levels (as used in cell culture conditions), 
over-activated ER- might create steric effects by continuously disturbing or shielding 
interaction of general transcription factors with the TATA element of NIS gene, resulting in 
a negative or down-regulatory effect. According to this hypothesis, among other genetic and 
epigenetic factors, the amount of ER- ligands would define the type of interactions 
(synergistic or antagonistic) and the outcome of interactions (up-regulatory or down-
regulatory) between ERE bound ER- and TATA bound general transcription factors. This 
might also provide some hints to understand why goiter is more common in females as 
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compared to males, or possible explanations related with molecular mechanisms leading to 
I- transport deficiencies (ITD) in females, seen with a higher prevalence during or after 
pregnancy (Patrick, 2008). 
 
NIS ERE   TATA Box 
-430 GCGGAGTCGC GGTGACCCGG GAGCCCAATAAATCTGCAAC CCACAATCAC GAGCTGCTCC 
 
Transcription start 
-370 CGTAAGCCCC AAGGCGACCT CCAGCTGTCA GCGCTGAGCA CAGCGCCCAG GGAGAGGGAC 
Fig. 1. Functional NIS ERE sequence is located in close proximity of NIS TATA box element 
in the promoter region. Human NIS gene proximal promoter region sequence is partly 
shown. Numbers indicate positions of nucleotides relative to NIS start (ATG) codon. The 
transcription start site is indicated in blue letter (G), TATA box element, and novel ERE 
sequences are indicated in red, and in writing above these sequences. Two inverted repeats 
(half sites) of the NIS ERE element located in minus strand are underlined in red.  
As mentioned above, NIS expression increases near the end of gestation, and mammary 
glands start actively transporting I- before delivery (Tazebay et al., 2000). After delivery, the 
main physiological regulator of NIS expression is suckling of nipples. In fact, after delivery, 
in rodent models suckling regulates NIS expression in a reversible way: when pups are 
separated from the mother for 48 hours, steady-state NIS levels drop below detection levels 
by Western blots. Subsequently, when pups and mother are reunited for 24 hours, NIS 
accumulation reaches back to its maximal levels (Cho et al., 2000; Tazebay et al., 2000). Both 
prolactin and oxytocin, two pituitary hormones that were shown to have up-regulatory 
effects on NIS expression in breast were released simultaneously in response to suckling 
(Wakerley et al., 1978). This creates a wonderful regulatory mechanism preventing 
unnecessary active transport of I- to mother’s milk once grown-up pups stop suckling.  
3. NIS expression in human breast cancer 
A high prevalence of NIS expression in human breast cancer combined with much lower 
prevalance in normal extratumoral tissues have been reported in many independent studies, 
and by using a variety molecular analysis methods. In a pioneering study, Tazebay et al. 
(2000) demonstrated a perchlorate inhibited NIS activity in experimental mammary 
adenocarcinomas in female transgenic mice carrying Murine Mammary Tumor Virus 
(MMTV)-promoter driven activated Ras oncogene or over-expressed Neu oncogene. These 
authors were able to follow in real-time the NIS specific accumulation of radiolabelled I- 
isotopes, or another substrate of the symporter, 99mTcO4-,  in mammary tumours of animals. 
These were also the first evidences regarding possible uses of radio-labelled substrates of 
NIS for imaging of non-thyroid tumours. Importantly, in the same study, also human breast 
tissue specimens were analyzed by immunobiochemical methods, and it was found that 
above 80% of invasive and ductal carcinoma in situ samples were expressing NIS, whereas 
only about 20% of non-cancerous samples adjacent to tumours were NIS-positive. Besides, 
none of the 8 normal specimens obtained by reductive mammoplasties were expressing NIS 
(Tazebay et al., 2000). In subsequent studies where larger cohorts and variety of molecular 
techniques were used, results were comparable to initial reports. Wapnir et al. (2003) 
analyzed NIS expression in a total of 202 human breast samples, and they reported a clear 
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NIS positivity in 76% of invasive breast carcinomas, 88% of ductal carcinomas in situ, and 
80% of fibroadenoma samples. Only one-out-of eight (13%) normal breast samples analyzed 
in the same study were weakly expressing NIS. More recently, endogenous NIS expression 
were analyzed in a subtype of breast carcinomas known as triple-negative breast cancer 
(Renier et al., 2010). This clinical-pathological subtype with the worst prognosis among 
breast cancer subtypes is commonly defined by the absence of ER, progesterone receptor 
(PR), and human epidermal growth factor receptor-2 (HER2) (Sorlie et al., 2003). In this 
study, Renier et al. (2010) demonstrated that 15 specimens out-of 23 were NIS positive (67% 
positivity), with 11/15 samples being strongly positive (47% of total), suggesting a potential 
use for NIS-dependent radio-ablative strategies against this aggressive tumour group. 
Independently, still another research group composed of Beyer and co-workers (2009) has 
analyzed NIS expression levels in 192 different breast cancer specimens found on tissue 
microarrays, with a particular focus on sub-cellular localization of NIS protein expressed in 
those samples. In this study, 72% of samples were found to express -at variable levels- the 
symporter, and in 28% of tissue samples NIS expression were reported to be null. Beyer et al. 
(2009) argued that according to their visual analysis of stained tissue sections only 27% of 
NIS-positive tumours the symporter had a cell surface (plasma membrane) localization, and 
in remaining samples NIS seemed to localize at a cytoplasmic compartment. This is in fact 
an important observation that could also bring some explanation to the discrepancy 
between high percentages of NIS positivity (around 80% overall) in breast tumours, whereas 
relatively low percentage of radionuclide uptake activity in patients (17-25%; see also 
below). Yet, it is arguable whether immuno-histochemical staining techniques and visual 
evaluations of stained tissue sections used as main analysis methods in the study of Beyer 
and co-workers (2009) could be taken as sufficient to comment on sub-cellular localization of 
a membrane protein. In future, precise cell science techniques with improved microscopy, 
and quantitative molecular methodologies would be essential in order to better establish 
quantities of NIS proteins found at variable sub-cellular localizations in breast 
cancer/normal samples coming from patients.  
In a recent and elegantly designed study, both relative levels of NIS expression in breast 
cancer samples (n=75), in fibroadenomas (n=15), and normal human samples (n=10) coming 
from premenopausal and postmenopausal patients, as well as correlations between 
expressions of the symporter gene and that of several proven or putative regulators of NIS 
ER-, retinoic receptors alpha and beta (RAR- and RAR-), thyroid hormone receptors 
alpha and beta (THR- and THR-) were assessed by quantitative molecular techniques by 
Ryan et al. (2011). Furthermore, these authors have tested results of their tissue analysis by 
treating two distinct mammary cancer cell culture models (ER/PR positive, HER2 negative 
T47D cells versus ER/PR negative, HER2 positive SK-Br-3 cells) with agonist of those 
regulators, and thus rigorously validated their findings in tissue analysis. Supporting 
previous in vivo and in vitro studies, expression of NIS, RAR-, RAR-, and ER- were 
found to be higher in breast cancer samples as compared to normal adjacent tissues. 
Moreover, a significant positive correlation was detected between NIS and these three 
transcriptional regulators, the highest correlation being between NIS and retinoid inducible 
factor RAR- (Ryan et al., 2011). These results were also tested by appropriate ligands used 
in mammary cell culture experiments, and they were largely validated (see part 5, below). 
Data obtained by Ryan and co-workers (2011) should certainly be taken into account when 
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deciding on how to better design novel approaches for increasing endogenous mammary 
cancer NIS expression in different neoplastic growth types by stimulation of appropriate 
nuclear receptors and other trans-acting regulatory factors. 
NIS protein was also demonstrated to be detectable in soft tissue metastasis of breast cancer. 
Renier and co-workers (2010) have carried-out an immuno-histochemical analysis on 28 
archival tumour samples obtained from breast cancer brain metastasis (BCBM). In this 
analysis, they have studied NIS positivity in BCBM tissues, and correlated it with ER, PR, 
and HER2/Neu status of specimens. 21/28 cases were reported to be expressing NIS. 
Among those, 9 were from triple-negative for ER/PR/HER2, and 12 were ER/PR-negative, 
but HER2 positive. ER/PR-positively stained group of brain metastatic samples did not 
express NIS protein. Again, these authors argued that only about 24% of NIS positive 
samples had plasma membrane staining. These studies provided invaluable preliminary 
results on differences of NIS protein localization in different patient samples, and future 
scientific studies addressing sub-cellular localization of NIS in BCBM tissues by using 
appropriate cell biology methods would be essential for a precise characterization of cellular 
localization of NIS in metastatic tissues. Yet, this study documents about 75% NIS positivity 
in BCBM, and certainly stands-out with its important implications on possible uses of NIS 
activity based diagnostic/therapeutic methods in breast cancer soft tissue metastasis cases. 
Functional NIS expression was also shown by in vivo scintigraphic imaging methods in 
human breast cancers and its soft tissue metastasis. Recent advances in methodologies and 
approaches concerning uses of radio-labelled NIS substrates in imaging and diagnosis of 
malignant tissue are described in the next section below.  
4. Human clinical trials on selective targeting of breast cancer by 
radionuclide substrates of NIS  
Specific targeting of tumours with anti-cancer agents is one of the major research areas in 
cancer biology. Selective targeting of thyroid cancer and its metastasis by radioisotopes of NIS 
substrates has been successfully developed by nuclear medicine and effectively used as a 
diagnostic/therapeutic method in fight with malignant thyroid disease. Immediately after the 
discovery that lactating mammary gland concentrates I- by the same transport mechanism 
operating in thyroid, and that the same symporter (NIS) is expressed in more than %80 human 
of breast cancer cases, there started translational medicine approaches for testing effectiveness 
of NIS activity based methodologies to diagnose and eradicate malignant breast disease in 
different groups of patients (Moon et al., 2001; and also see the clinical trial sponsored by 
Stanford University, entitled: Scintigraphic Assessment of I- Transport in Metastatic Breast 
Cancer and Evaluation of Ablative Therapy: Radioiodide Imaging Study; clinicaltrials.gov 
identifier number NCT00185809, http://www.clinicaltrials.gov). Optimistic results from 
several studies on uses and effectiveness of radioiodide based therapeutic techniques in non-
thyroid cancers that externally received NIS gene by viral delivery methods (Spitzweg et al., 
2000; Faivre et al., 2004; Dwyer et al., 2006) gave further hopes to researchers who try to 
develop NIS based diagnostic/therapeutic tools for breast cancer management.  
Several groups have assessed whether NIS substrates were accumulated by breast tumours 
in human subjects, at high enough concentrations, durations and specificities in order to 
permit imaging or therapy of malignant tissues by these substances. Moon et al. (2001) have 
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investigated the correlation between 99mTcO4- uptakes and NIS mRNA expressions in breast 
cancer patients. Among 25 patients studied, 99mTcO4- scintigraphy revealed positive uptake 
in 4 patients. There were a positive correlation between 99mTcO4- uptake and NIS gene 
mRNA expression levels in tumours, and positive uptake tumours expressed higher levels 
of NIS as compared to negative uptake breast tumours (Moon et al., 2001). This was an 
important result indicating that a substrate of NIS, 99mTcO4-, could actually be used in 
imaging of breast tumours. However, even though in all previous tissue analysis studies 
NIS positivity in breast cancer samples were reported to be around 80%, in the study carried 
by Moon et al. (2001) only in 17% of breast cancer patients tumours were visible by 99mTcO4- 
imaging. In another study, Upadhyay et al. (2003) investigated 99mTcO4- transport capacities 
of tumours in a study comprised of 12 female patients (age 33-58 years) with infiltrating 
ductal carcinomas confirmed by fine needle aspiration cytology (FNAC) and subsequent 
histopathological analysis. Out of these 12 patients, samples obtained from 5 patients were 
analyzed by molecular techniques investigating NIS expression at transcriptional and 
translational levels, and scintigraphic imaging were performed in 4 out-of 5 patients prior to 
mastectomy. These authors reported both high NIS expression levels in all 4 tumours 
analyzed by scintigraphy, and high ability to concentrate 99mTcO4- in tumour tissues. 
Because of the small sample size used in this study, it is very hard to comment on ratios 
related with NIS positivity versus radionuclide uptake positivity. Nevertheless, the study 
indicated possibilities of using 99mTcO4- for imaging purposes in breast cancer. 
So far, only the study of Wapnir et al. (2004) addressed whether NIS expressing metastatic 
breast tumours could be detected by using radioiodides (123I- and 131I-) or 99mTcO4- in 
scintigraphic analysis. These authors investigated NIS activity in BCBM tissues of 27 women 
by administering either 99mTcO4- or 123I- followed by a whole body scintigraphic analysis. I- 
uptake was noted only in 25% of NIS expressing BCBM tissues (2 out-of 8). Apparently, 
nearly 30% of breast cancer related deaths demonstrate central nervous system involvement 
on autopsy, and the treatment of BCBM is particularly challenging because many anticancer 
drugs have limited access to the central nervous system (Renier et al., 2010). Therefore, 
systemic agents capable of crossing the blood-brain barrier, such as I- or 99mTcO4-, could 
especially be important if they are effective against NIS positive breast cancer subtypes that 
metastasize to the brain.  
Importantly, in the investigations carried-out by Wapnir et al. (2004), these authors also 
succeded to suppress thyroidal uptake of radiolabelled tracers by administering thyroxine 
(T3) and methimazole (an inhibitor of I- organification in thyroid) to patients under clinical 
trials. Suppression of thyroidal uptake in this study by a hormone regiment have in fact 
answered present discussions on whether it would be possible to protect healthy thyrocytes 
(which take-up and organify I-) in case radioiodide based therapies are used to treat non-
thyroidal tumours. If thyroidal cells were compromised during administration of radio-
labelled NIS substrates, then the patients would need to depend on thyroid hormone 
medications for the rest of their lives. This is of course not preferable, and it was important 
to find ways of successfully protecting healthy thyroids of patients under clinical 
investigations. It seems in future clinical trials, integrity of thyroid cells could be protected 
by inhibiting thyroidal activity of NIS with hormone treatment regiments similar to the ones 
used in this study, while the non-thyroid origin tumour is targeted by cytotoxic NIS 
substrates. There is in fact a pilot radioiodide based breast cancer imaging clinical trial 
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currently carried-out under sponsorship of Stanford University at U.S. where a combination 
of T3/methimazole regiment would be used for protection of thyrocytes (Pilot Study to 
Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT; 
clinicaltrials.gov identifier number: NCT00725946; http://www.clinicaltrials.gov). 
5. Modulation of NIS expression in breast cancer cell models and in 
xenograft tumors in mice  
NIS expression is present in about 80% of breast cancers suggesting that breast cancer 
patients may benefit from NIS-mediated radioiodide imaging and/or therapeutic methods. 
Nevertheless, only 17-25% of NIS positive breast tumors had detectable radionuclide 
transport activity as assessed by scintigraphic imaging (Moon et al., 2001; Upadhyay et al., 
2003; Wapnir et al., 2004). Currently, there is a clear need to identify possible mechanisms 
underlying this discrepancy between NIS expression and NIS-mediated radionuclide uptake 
activity. Previous studies (reviewed above) based on analysis of breast cancer samples 
suggested that, in addition to NIS mRNA and protein expression, post-translational 
modification(s) of the symporter and appropriate membrane targeting are likely to be 
important for the substrate transport activity of NIS. Differential levels of NIS expression 
may account for variable cell surface NIS levels among breast cancer samples, and particular 
hormone combinations may be needed to upregulate expression and activity of the 
symporter at higher levels for successful future theraputic or diagnostic applications 
involving NIS activity. 
Results from different laboratories have revealed that both the expression of mammary 
gland NIS gene at the transcriptional level, and the post-translational 
trafficking/localization of NIS to plasma membrane are tightly regulated in a cellular 
context and an extracellular stimuli dependent way (Tazebay et al., 2000; Riedel et al., 2001; 
Kogai et al., 2004; 2008; Dentice et al., 2004; Alotaibi et al., 2006; 2010; Willhauck et al., 2011). 
The list of hormones that were shown to have an upregulatory effect on NIS expression in a 
variety of model mammary gland cell lines and in animal experiments (xenografted and 
normal) include lactogenic hormones (prolactin and oxytocin), steroids (estrogens), 
retinoids, dexamethasone (Dex), and carbamazepine.  
In initial animal experiments, lactogenic hormones prolactin and oxytocin were proven to 
upregulate NIS expression in the mammary tissue (see above, Cho et al., 2000; Tazebay et al., 
2000). Both the two hormones were tested for their upregulatory activities by Cho et al. 
(2000) on human breast cancer cultures kept on collagen gels. In this experimental set-up, 
individual prolactin (500ng/ml) and oxytocin (100 ng/ml) treatments have positively 
affected NIS gene regulation by inducing it at the transcriptional level, but a combination of 
the two hormones failed to do so. A significant induction of NIS gene by prolactin was also 
reported by Arturi et al. (2005) in a mammary cancer cell line, MCF-7. This is a cell line 
derived from mammary adenocarcinoma metastatic to a pleural effusion of lung, and it is 
one of the most common ER-positive breast cancer cell line models. This cell line, together 
with MDA-MB-231 cells which are ER-negative cell models, is used in most of the studies 
addressing upregulatory effects of a variety of substances on NIS gene regulation (for 
instance see, Alotaibi et al., 2006; Arturi et al., 2005; Kogai et al., 2006). Using MCF-7 cells, 
both our group and Kogai et al. (2005) have tested the effects of 17--estradiol (at 10 nM 
concentration; one of the most potent estrogens) on NIS gene induction, and neither of the 
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two groups have seen a positive regulatory effect of this estrogen on the induction of the 
gene when introduced to cell lines in culture (Alotaibi et al., 2006). However, independent of 
the presence of ligand, ER plays a very critical regulatory role on NIS expression in a 
number of mammary gland cell models (see above, and also Alotaibi et al., 2006). The fact 
that some ER-negative tumours have upregulated NIS expression (Tazebay et al., 2000; Ryan 
et al., 2011) indicate that ER is not absolutely essential for inducibility of NIS in breast 
tumours, and in tumor milieu in vivo other ER-independent molecular mechanisms may 
operate making NIS induction possible. Recently, in response to 17--estradiol 
administration to ER-negative and ER-positive mammary cancer model cell lines, Ryan and 
co-workers (2011) have observed a 3 to 6-fold increased NIS expression in T47D cells (ER-
positive), and about 5-fold increase in Sk-BR-3 cells (ER-negative). Because they observed 
estradiol inducible NIS expression in Sk-BR-3 mammary cell line which is an ER-negative 
cell model, they argued that similar to some breast tumours, ER may not be essential for 
inducibility of NIS in this cell line model as well, and additional mechanisms which bypass 
ER dependent regulatory components for activation of NIS gene may be operating in those 
cells.  
Retinoids have a robust effect on functional NIS induction in human MCF-7 cells (Kogai et 
al., 2000; 2004; 2005; 2008). These compounds are active metabolites of vitamin A, and they 
have been used in animal models and humans as differentiation agents for various types of 
cancers including breast cancer (Mark et al., 2006). The typical retinoid pathway involves the 
ligand-activated nuclear receptors belonging to retinoic acid receptor family (RAR) and 
retinoid-X-receptor family (RXR). RAR and RXR form heterodimers, and bind 
corresponding RA or RXR response elements (RARs) at cis-acting regulatory DNA sites and 
activate gene transcription (Mark et al., 2006). All-trans retinoic acid (tRA; at 1µM) stimulates 
NIS induction up to 10-fold above the baseline in ER-positive MCF-7 cells, but it can not 
induce expression of the symporter in ER-negative model, MDA-MB-231 (Kogai et al., 2000; 
2004), and this is because ER-positivity is absolutely essential for retinoid responsive 
upregulation of NIS virtually in all breast cancer cell line models (Alotaibi et al., 2006), 
except Sk-BR-3 (Ryan et al., 2011). In fact, Kogai et al. (2005) analyzed the isoform specificity 
of retinoid receptors for the upregulation of NIS gene expression by using isoform selective 
retinoid receptor ligands. They reported that a RAR-/ agonist (AGN190168) is a more 
potent inducer of NIS than a RAR- agonist (AGN195183) or a RAR- agonist (AGN194433), 
indicating a central role to RAR- in upregulation of NIS by retinoids. In line with these 
results, Ryan et al. (2011) have reported a robust positive correlation between NIS 
upregulation and RAR- gene expression in human breast tissue samples (n=100) that they 
have analyzed by quantitative real-time PCR methods.  
Even though, RAR and RXR were known to upregulate NIS expression since a while, cis-
acting elements directly interacting with these nuclear receptors were only identified 
recently (Alotaibi et al., 2010). This delay in identification of RA responsive elements (RARE) 
that activate NIS transcription could be due to uncommon positioning of those cis-acting 
sites  in multiple intronic positions in NIS gene. In our recent work, we have described that a 
functional RARE is present in the first intron of human NIS gene, and it seems there are at 
least six others in other introns of this gene (Alotaibi et al., 2010). In fact, initially we found 
three putative RAREs in the first intron intron. The first was a perfect DR2-type consensus 
RARE sequence (AGGTCAggAGTTCA), the second was a DR10-type sequence 
[AGGTGG(n10)AGGTCA], and the third was again a DR2-type sequence identical to the 
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first one (AGGTCAggAGTTCA), and it was overlapping with the second half-site of the 
previous putative RARE. By using a series of luciferase reporter constructs containing 
different fragments of this intronic region, as well as in vitro mutagenized versions of these 
putative RARE sequences, we have demonstrated that the third RARE which is located at 
+1222 relative to the start codon of NIS was a functional RARE. In MCF-7 cells transfected 
with a luciferase reporter construct containing this element, tRA treatment resulted in an 
increase of about 4-fold when compared to cells treated with DMSO vector. We also 
investigated the potential of this intronic RARE to activate transcription through the native 
NIS minimal promoter. For this purpose, we constructed reporter plasmids containing the 
minimal NIS promoter (218 bp of NIS upstream region between -260 bp and +42 bp relative 
to transcription start site, and capable of initiating transcription as assessed by previous 
functional reporter assays. As anticipated, the intronic element significantly activated NIS 
promoter in response to tRA when positioned either at the 5’ or at 3’ of the reporter gene, in 
agreement with the function of an enhancer. Furthermore, by electromobility shift assays 
and chromatin immunoprecipitation (ChIP) methods, we have shown that both RARs and 
RXR interacts with this RARE in response to tRA (Alotaibi et al., 2010). Altogether these 
findings clearly indicated that the DR2-2 element that is present in the first intron of NIS is 
an important RARE in regulation of human NIS gene. Similar RARE sequences were also 
present in introns 5, 7, 8, 12, 13 and 14 of human NIS gene (some having identical sequences 
with RARE found in intron 1). All these sequences interact with RARs and RXR, and 
eventually with the RNA Polymerase II (PolII) in ChIP assays at different time points in 
response to tRA administration to cells (Fig. 2). Earlier work by others, and results obtained 
by Alotaibi et al. (2010) clearly indicate that molecular mechanisms governing NIS 
expression involve a number of classical and intronic elements that regulate temporal and 
spatial expression, and they are likely to be more complex than previously anticipated. 
Future experiments will show whether the activities of intronic enhancers lead also to a 
tissue or cell-type-specific regulation of NIS. 
 
 
Fig. 2. Nuclear receptors and RNA Pol-II interact with NIS intronic elements in a dynamic 
manner during the initiation of transcription. MCF-7 cells grown in steroid-free and phenol-
red-free DMEM were treated either with DMSO (time 0) or with tRA for 15, 30 and 60 min 
and used for ChIP analysis using RARa and RXR and RNA Pol-II specific antibodies. mRNA 
was isolated from a fraction of the cells used for this analysis, NIS expression was 
normalized to the levels of GAPDH, and presented as relative fold induction compared to 
DMSO-treated samples. A schematic representation of ChIP data depicting the events of 
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transcription initiation of NIS in response to tRA stimulation is shown. Numbers indicate 
introns studied, asterisks above numbers indicate RA responsive elements with identical 
DNA sequences; AGGTCAnnAGTTCA. Parallelograms with question mark represent 
unidentified interacting proteins. The figure is reproduced from Alotaibi et al., 2010, Intronic 
Elements in the NIS Gene Interact with Retinoic Acid Receptors and Mediate Initiation of 
Transcription. Nucleic Acids Research, Vol. 38 (10), pages 3172-3185. Reprinted with 
permission from The Oxford University Press © 2010.  
In vivo studies with MCF-7 xenograft tumours in immunodeficient (CD1 nu/nu) mice have 
indicated that systemic tRA treatment increases radioiodide (125I-) accumulation capacities of 
xenografts about 15 fold above background, and this level is sufficient for selective imaging 
of tumours with 125I-. Administration of dexamethasone (Dex), and carbamazepine (CBZ) 
together with tRA increased both iodide uptake by NIS, and NIS mRNA expression even 
more. In response to Dex and CBZ administration, tRA induced I- uptake via NIS have 
increased about 12 fold in xenograft tumours in experimental animals, clearly indicating 
that the combination of an RAR isoform selective ligand and Dex and Cbz has a potential to 
provide a more effective induction of NIS, and it provides an important improvement for 
the effective use of symporter in theraputic/diagnostic medical approaches (Kogai et al., 
2005; Willhauck et al., 2008; 2011).  
6. Future strategies for development of NIS activity based diagnostic and 
therapeutic methods 
Detection of radioiodide transport in thyroid cancer tissues at the beginning of 1940’s 
marked the beginning of nuclear medicine as a discipline in medical sciences, by allowing 
the use of radioiodide and other selective radionuclide substrates of this symporter (for 
instance, 99mTcO4-) in successful management of thyroid cancers and their metastasis. 
Similarly, recent detection of functional NIS expression and radioiodide accumulation in 
breast cancer tissues provide important opportunities for development of novel adjuvant 
therapies and/or detection methods based on breast cancer specific NIS activity. Routine 
and successful use of radioiodide in hospitals to evaluate and cure thyroid cancer cases for 
more than 60 years, make it an even more attractive substance to be worked on for 
developing future innovative methodologies for implementation to non-thyroidal cancers. 
Furthermore, as I described in the previous section, a number of substances (especially 
retinoids and glucocorticoids) modulating NIS expression and enhancing radioiodide 
transport activities in mammary cancer cell models and xenografted animals were already 
developed, and these advances in basic research are currently waiting to be brought to "bed 
side" by translational medicine approaches. 
A number of clinical studies have already addressed use of radioiodide in scintigraphic 
detection of breast tumours, and breast cancer metastasis in vivo (see above). Even though 
data coming from these studies have led to optimistic conclusions on prospective uses of 
131I- radioablation techniques on at least some breast cancers and their metastasis, to our 
knowledge, a clinical trial subjecting breast cancer patients to radioiodide based ablation 
studies has not yet taken place.  
As presented through-out the text above, there are three main problems that have to be 
solved for effective and routine use of radio-iodide (or other cytotoxic NIS substrates) in 
management breast cancers: 1) discrepancies in percentages of NIS expressing tumour 
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tissues (around 80%) versus percentages of cancers taking up radio-iodide (17-25%); 2) 
problems associated with low or insufficient cumulative I- uptakes in breast cancers 
(0.00131% ID/ml; Renier et al., 2009), making it difficult to achieve a therapeutic effect; and 
3) reported accumulation of radio-iodide in some benign fibroadenoma of breast (Berger et 
al., 2006), which brings problems of achieving sufficient malignant tissue specificity in 
diagnosing and targeting breast cancers with NIS substrate radionuclides. A fourth issue 
may be protection of healthy thyroid from cytotoxicity of agents transported by NIS in 
imaging or treatment of non-thyroidal tumours, as thyrocytes very robustly and 
constitutively express functional NIS (for a review see Kogai et al., 2006). In fact, this fourth 
point was addressed in studies carried out by Wapnir and co-workers (2004), and it has 
been shown that uptake of solutes to thyroid via NIS could selectively be down regulated by 
administering a combination of thyroid hormones and I- organification inhibitor 
methimazole to imaged patients. Therefore, it seems in future studies this final issue could 
be at least easily solved with some optimization of hormone/methimazole combinations. 
However, solutions for the remaining three problems should be rigorously addressed in 
future clinical, translational, and basic research studies. 
Regarding which subtype of breast cancer tissue responds best to, and therefore more 
suitable for, imaging/treatment with NIS substrate agents, the work of Ryan et al. (2011) 
indicated that cancers expressing RARs and ERs are amenable to radioiodine based imaging 
techniques. However, it has been shown by their study that the group of tissues that express 
RARs, ERs, and finally NIS at maximal levels were benign fibroadenoma samples. This 
suggests that together with radioiodine scintigraphic analysis of the mammary, additional 
analysis methods would be essential for differentiating radio-iodide transporting benign 
tissue from the malignant breast cancer. In future prospective approaches, once the 
possibility of fibroadenoma of the breast is eliminated, radio-iodide uptake in malignant 
cancerous tissue of the breast could be upregulated by hormone combinations (retinoids, 
dex, and cbz) as previously suggested by independent works of Kogai et al. (2004), and 
Willhauck et al. (2011). That could perhaps solve the problem of discrepancy between NIS 
expression and NIS-positive tumour radio-iodide uptake, leading to a robust expression of 
functional NIS in malignant breast tissue, which could then permit use of 131I- dependent 
ablation strategies for curing the disease. In the meantime, healthy thyroid of the patients 
could be protected from ablative effects of radionuclides by administering the hormone 
regiment containing thyroxine and methimazole, as suggested by Wapnir et al. (2004).  
The beta-emitter radionuclide Rhenium-188-perrhenate (188RheO4-), and the alpha emitter 
Astatine-211 (211As) have shorter half lives (17 hours and 10,5 hours, respectively) as compared 
8 days half-life of the beta emitter 131I- (Dadachova and Carrasco, 2004). 188RheO4- have also 
previously been shown to be effective on NIS expressing mammary cancers of transgenic mice 
bearing polyoma-middle-T oncoprotein, as this radiosope have significantly inhibited growth 
of these experimental tumours (Dadachova et al., 2005). Therefore, in future studies, a variety 
of radionuclides that are transported by NIS could be selected to be used in these possible 
novel applications targeting malignant breast cancer cells with least possible side-effects, while 
having high specificity, improved efficiency, and remarkable safety.  
7. Conclusion 
Breast cancer management involves chemotherapeutic procedures before or subsequent to 
surgery with the aim of ablating micro-metastatic cells and improving disease free overall 
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survival of the patient. The administration of cytotoxic agents used in breast cancer 
chemotherapy is usually by venal intervention, and it can cause significant pain and side 
effects. Therefore, development and introduction of alternative strategies that target breast 
cancer cells with high specificity, less toxicity to healthy tissues, and with less overall side-
effects is important. Because of previous, and decades long, clinical work in diagnosing and 
treating thyroid cancers by radioisotope substrates of NIS, use of NIS transported 
radionuclides could offer novel prospective breast cancer treatment modalities with 
advantages such as easier administration procedures, and relatively less side-effects as 
compared to current chemotherapeutic drugs.  
Recent scientific studies on molecular biology and regulation of NIS expression in breast 
cancer models have very clearly shown the important potential of NIS activity based novel 
radiotherapy techniques in management of malignant breast disease. A number of 
lactogenic hormones, estradiol, retinoids, and glucocorticoids were shown to enhance 
radioiodide transport in breast cancer cells, as well as in in vivo models. Increased 
understanding of molecular mechanisms that upregulate NIS expression in response to 
these hormones and ligands, and enhance the activity of the symporter in breast tissue as 
well as in breast cancer metastasis will be essential for the development and improvement of 
methods that will involve use of NIS activity and cytotoxic substrates for imaging and 
therapeutic purposes in breast cancer clinics. 
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